Centre de Recherche en Cancérologie de Lyon, INSERM U1052/CNRS UMR 5286 Centre Léon Bérard , Lyon , France ; Université Lyon 1, Université de Lyon , Lyon , France ; ViroScan3D , Trévoux , France.
Centre de Recherche en Cancérologie de Lyon, INSERM U1052/CNRS UMR 5286 Centre Léon Bérard , Lyon , France ; Université Lyon 1, Université de Lyon , Lyon , France ; ProfileXpert, SFR-Est, CNRS UMR-S3453, INSERM US7 , Lyon , France.
Front Med (Lausanne). 2015 Aug 10;2:54. doi: 10.3389/fmed.2015.00054. eCollection 2015.
Changes in microRNAs (miRNAs) expression in many types of cancer suggest that they may be involved in crucial steps during tumor progression. Indeed, miRNAs deregulation has been described in pituitary tumorigenesis, but few studies have described their role in pituitary tumor progression toward aggressiveness and malignancy. To assess the role of miRNAs within the hierarchical cascade of events in prolactin (PRL) tumors during progression, we used an integrative genomic approach to associate clinical-pathological features, global miRNA expression, and transcriptomic profiles of the same human tumors. We describe the specific down-regulation of one principal miRNA, miR-183, in the 8 aggressive (A, grade 2b) compared to the 18 non-aggressive (NA, grades 1a, 2a) PRL tumors. We demonstrate that it acts as an anti-proliferative gene by directly targeting KIAA0101, which is involved in cell cycle activation and inhibition of p53-p21-mediated cell cycle arrest. Moreover, we show that miR-183 and KIAA0101 expression significantly correlate with the main markers of pituitary tumors aggressiveness, Ki-67 and p53. These results confirm the activation of proliferation in aggressive and malignant PRL tumors compared to non-aggressive ones. Importantly, these data also demonstrate the ability of such an integrative genomic strategy, applied in the same human tumors, to identify the molecular mechanisms responsible for tumoral progression even from a small cohort of patients.
许多类型癌症中 microRNAs(miRNAs)表达的变化表明它们可能参与肿瘤进展的关键步骤。事实上,已经描述了垂体肿瘤发生中 miRNAs 的失调,但很少有研究描述它们在垂体肿瘤向侵袭性和恶性进展过程中的作用。为了评估 miRNAs 在催乳素(PRL)肿瘤进展过程中分层事件级联中的作用,我们使用整合基因组方法将临床病理特征、全局 miRNA 表达和相同人类肿瘤的转录组谱联系起来。我们描述了在 8 个侵袭性(A,2b 级)与 18 个非侵袭性(NA,1a、2a 级)PRL 肿瘤相比,一个主要 miRNA,miR-183 的特异性下调。我们证明它通过直接靶向 KIAA0101 作为一种抗增殖基因,KIAA0101 参与细胞周期激活和抑制 p53-p21 介导的细胞周期阻滞。此外,我们表明 miR-183 和 KIAA0101 的表达与垂体肿瘤侵袭性的主要标志物 Ki-67 和 p53 显著相关。这些结果证实了与非侵袭性肿瘤相比,侵袭性和恶性 PRL 肿瘤中增殖的激活。重要的是,这些数据还证明了这种整合基因组策略在相同人类肿瘤中的应用能够识别肿瘤进展的分子机制,即使在患者数量较少的情况下也是如此。